Sims Andrew John Hugh MacIntyre 4

What Happened

• Andrew John Hugh MacIntyre Sims, Chief Financial Officer of Plus Therapeutics (PSTV), was awarded a total of 699,083 derivative units on Feb 25, 2026 (reported as two awards of 349,542 and 349,541 RSUs). Each unit is a contingent right to receive one share of common stock; the awards were reported at $0 per unit (no cash paid on grant). This is a compensation/award grant rather than a market purchase or sale.

Key Details

• Transaction date: 2026-02-25; Filing date (Form 4): 2026-02-27 (filed within the typical 2-business-day window).
• Award amount: 349,542 RSUs + 349,541 RSUs = 699,083 RSUs; reported price $0.00 (derivative award).
• Vesting (Footnote F1): RSUs vest ratably over 12 quarters in equal 1/12th increments, beginning April 1, 2026, then quarterly thereafter.
• Additional footnote (F2) in the filing describes option vesting rules (1/48th monthly over four years and vest-on-change-of-control) — the primary reported awards here are RSUs per F1.
• Shares owned after transaction: not specified in the reported Form 4.

Context

• RSU grants are common executive compensation and are primarily a retention tool; they do not represent an immediate market purchase or sale and do not by themselves indicate a buying or selling signal. Because these RSUs vest over multiple quarters, actual shares (and any related tax events) will occur as vesting milestones are reached.